ClinicalTrials.gg
CompletedNCT00570310Updated May 7, 2015Results posted

Neuropathic Pain Syndrome Patient Study (MK-0000-072)

A Phase 1 interventional study of Comparator: pregabalin and Comparator: Placebo (unspecified) in Neuralgia, Postherpetic, Diabetic Neuropathy and Painful Small-Fiber Neuropathy, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing pregabalin in Neuralgia, Postherpetic — 3 open to participants now, 3 under way, 1 of them phase 3. Pregabalin · Neuralgia, Postherpetic.

Enrollment
11th of 15
104 · median 126
Started
2007
with 2 others
Phase 1
2 of 15
1 open now
Registered
6th of 15
by date
Lead sponsor
1 of 15
Merck Sharp & Dohme LLC

Among the 15 studies testing pregabalin in Neuralgia, Postherpetic, this one is the 11th largest by enrollment, is one of 3 that started in 2007, is one of 2 in phase 1, and was the 6th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

3 of the 15 studies testing pregabalin in Neuralgia, Postherpetic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing pregabalin in Neuralgia, Postherpetic, or all of them as a file.
02

Study summary

The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain.

03

Conditions studied

  • Neuralgia, Postherpetic
  • Diabetic Neuropathy
  • Painful Small-Fiber Neuropathy
  • Idiopathic Distal Sensory Polyneuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has moderate to severe nerve pain due to one of the following conditions: Postherpetic neuralgia, Painful diabetic neuropathy, Small fiber neuropathy or idiopathic distal sensory polyneuropathy
  • Patient is able to complete questionnaires in either English or Spanish
  • Patient is at least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Patient is either pregnant or breastfeeding
  • Patient has a history of angioedema (swelling beneath the skin surface) or peripheral edema (foot, leg, and/or ankle swelling)
  • Patient has a history of congestive heart failure
  • Patient has a seizure disorder
  • Patient has a history of drug and/or alcohol abuse within the past 1 year
  • Patient failed treatment due to lack of pain relief with more than three drugs for nerve pain
  • Patient has had cancer (except basal cell carcinoma) within the past two years
  • Patient anticipates the need for surgery while participating in the study
  • Patient has a reported history of , C, or infection
  • Patient has another type of pain that is more painful than the nerve pain
  • Patient has generalized anxiety disorder, untreated depression, psychosis, or post-traumatic stress disorder
  • Patient is involved in litigation or receives worker's compensation related to nerve pain
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Active comparator
    A

    Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period.

    Drug: Comparator: pregabalin

  • Placebo comparator
    B

    Patients in Group B will be treated with placebo.

    Drug: Comparator: Placebo (unspecified)

Interventions

  • pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks

  • DrugComparator: Placebo (unspecified)

    pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks

06

What researchers measure

Primary outcomes

  1. Daily Evening Patient Reported Pain Intensity Scores

    Change from mean of last 3 days of maintenance period to last 3 days of double-blind period; Pain Intensity was rated on a 0-10 numeric rating scale (NRS: 0=no pain, 10=worst pain you can imagine)

    Time frame: Baseline and 6 Weeks

Secondary outcomes

  1. 'Time to Efficacy Failure' During the Randomized Withdrawal Portion of the Study

    Time to treatment failure (3 day mean of average 24 hour pain intensity ≥ 4 with at least a 30% increase relative to the last 3 days prior to randomization)

    Time frame: 6 Weeks

07

Results

Posted Feb 5, 2010

Participant flow

Last Patient Entered: 06-Dec-07 Last Patient Last Visit: 11-Sep-08 # Sites: 20 sites randomized at least 1 patient. 21 sites screened at least 1 patient

Participant flow — Overall Study
MilestonePregabalinPlacebo
Started5351
Completed5145
Not completed26
Withdrew: Adverse event12
Withdrew: Lack of efficacy14

Outcome measures

PrimaryDaily Evening Patient Reported Pain Intensity Scores

Change from mean of last 3 days of maintenance period to last 3 days of double-blind period; Pain Intensity was rated on a 0-10 numeric rating scale (NRS: 0=no pain, 10=worst pain you can imagine)

Time frame:
Baseline and 6 Weeks
Reported as:
Least squares mean · Units on a Scale
Daily Evening Patient Reported Pain Intensity Scores
Units on a ScalePregabalinPlacebo
Daily Evening Patient Reported Pain Intensity Scores0.14 (-2.00 to 4.33)1.57 (-1.83 to 8.00)
Statistical analysis
  • Pregabalin vs Placebo · ANOVA · p = 0.003 (1-sided, alpha = 0.05) · Mean difference (final values): -1.42 · 90% CI -2.25 to -0.60Primary Hypothesis: In 'primary responder population', pregabalin is superior to placebo in maintaining pain control measured by change (3-day average: end of the randomization period versus end of maintenance period) in evening pain intensity.
Secondary'Time to Efficacy Failure' During the Randomized Withdrawal Portion of the Study

Time to treatment failure (3 day mean of average 24 hour pain intensity ≥ 4 with at least a 30% increase relative to the last 3 days prior to randomization)

Time frame:
6 Weeks
Reported as:
Least squares mean · Days
'Time to Efficacy Failure' During the Randomized Withdrawal Portion of the Study
DaysPregabalinPlacebo
'Time to Efficacy Failure' During the Randomized Withdrawal Portion of the Study15.54 (3 to 21)7.87 (3 to 21)
Statistical analysis
  • Pregabalin vs Placebo · ANOVA · p = <0.001 (1-sided, alpha = 0.05) · Mean difference (final values): 7.67 · 95% CI 5.26 to 10.08

Adverse events

Collected over The reported AEs were collected after patients were randomized to the double-blind withdrawal period of the study. AEs that were collected prior to randomization are not reported in this document.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—0/51 (0%)37/51 (72.5%)
Placebo—1/53 (1.9%)36/53 (67.9%)
Most frequent serious events
Most frequent serious events
EventPregabalinPlacebo
ArrhythmiaCardiac disorders0/511/53
Most frequent other events
Showing 10 of 88
Most frequent other events
EventPregabalinPlacebo
DizzinessNervous system disorders10/5111/53
SomnolenceNervous system disorders8/517/53
ConstipationGastrointestinal disorders6/512/53
Dry MouthGastrointestinal disorders6/512/53
Oedema PeripheralGeneral disorders5/513/53
FatigueGeneral disorders4/514/53
Vision BlurredEye disorders3/514/53
VertigoEar and labyrinth disorders3/510/53
NauseaGastrointestinal disorders3/511/53
Weight IncreasedInvestigations3/512/53

Baseline characteristics

Age, Continuous
Age, Continuous(years)PregabalinPlaceboTotal
Mean61.7 ± 10.859.3 ± 11.060.5 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinPlaceboTotal
Female81422
Male221840
Body Mass Index
Body Mass Index(kilograms/meter^2)PregabalinPlaceboTotal
Mean32.6 (20.9 to 49.3)31.3 (18.5 to 49.5)31.9 (18.5 to 49.5)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hewitt DJ, Ho TW, Galer B, Backonja M, Markovitz P, Gammaitoni A, Michelson D, Bolognese J, Alon A, Rosenberg E, Herman G, Wang H. Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain. 2011 Mar;152(3):514-521. doi: 10.1016/j.pain.2010.10.050. Epub 2010 Dec 23. PubMed 21185118 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2007
First posted
Dec 10, 2007
Start
Dec 2007
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Feb 5, 2010
Last update
May 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00570310
Responsible party
Sponsor
First posted
Dec 10, 2007
Start date
Dec 2007
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Feb 5, 2010
Last update
May 7, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion